Repeatability, reproducibility and analytic standards for biomarker development- Abbas Bandukwala

International Workshop on NASH Biomarkers 2018

Linking “intended use” to evidence needed for bringing a biomarker to market- John Sninsky, PhD

International Workshop on NASH Biomarkers 2018

Reporting standards: STARD & TRIPOD- Patrick Bossuyt, PhD

International Workshop on NASH Biomarkers 2018

Quality standards for imaging studies- Claude Sirlin, MD

International Workshop on NASH Biomarkers 2018

Case definitions for use as reference standards- Mohammed Siddiqui, MD

International Workshop on NASH Biomarkers 2018

Defining the reference standard for biomarker development - Histology versus clinical outcomes- Kathleen Donohue, MD

International Workshop on NASH Biomarkers 2018

A Context of Use Framework for Bioanalytical Validation of the CK18 Apoptosis Biomarker for NASH Drug Development- Sumit Kar

International Workshop on NASH Biomarkers 2018

Serum markers of collagen formation are associated with the severity of Liver fibrosis and Non-Alcoholic Steatohepatitis (NASH) histological features and to impaired renal function (IRF) in a NAFLD cohort- Samuel Daniels

International Workshop on NASH Biomarkers 2018

What is needed to link device approval to clinical application approval?- David Litwack, PhD

International Workshop on NASH Biomarkers 2018

Algorithm to identify non-alcoholic steatohepatitis (NASH) patients with a NAS≥4 and F≥2: algorithm derived in an American screening cohort and validation in a British non-alcoholic fatty liver disease (NAFLD) cohort- Celine Fournier

International Workshop on NASH Biomarkers 2018

Study design to validate biomarkers of therapeutic response for pre-cirrhotic NASH- Brent Tetri, MD

International Workshop on NASH Biomarkers 2018

Study design to validate biomarkers of therapeutic response in cirrhosis due to NASH- Detlef Schuppan, MD, PhD

International Workshop on NASH Biomarkers 2018

Defining therapeutic response in precirrhotic and cirrhotic NASH- Manal Abdelmalek , MD

International Workshop on NASH Biomarkers 2018

The clinical need for integrated assessment of NASH diabetes and heart disease- Arun Sanyal, MD, MBBS

International Workshop on NASH Biomarkers 2018

Use of plasma PRO-C3, PRO-C5, and PRO-C6 for the diagnosis and follow-up of fibrosis stage in patients with nonalcoholic fatty liver disease (NAFLD)- iana Leeming

International Workshop on NASH Biomarkers 2018

Neoepitope fragments of extracellular matrix as markers of fibrosis in chronic liver disease: Insights into clinical and preclinical utilization for unfolding disease pathogenesis - Diana Leeming, PhD

International Workshop on NASH Biomarkers 2018

Feasibility of Using Deep-learning-based Techniques for Liver Couinaud Segmentation and Proton Density Fat Fraction (PDFF) Estimation- Hashem Almahmoud

International Workshop on NASH Biomarkers 2018

Repeatability and Reproducibility of Multiparametric Magnetic Resonance Imaging of the Liver- Andrea Dennis

International Workshop on NASH Biomarkers 2018

FDA perspective on parallel review (Not available)- Rochelle Fink, MD, JD

International Workshop on NASH Biomarkers 2018

International Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018

HBV: diagnostics, management and screening- Marion Peters, MD

International Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018

Liver care in HIV - management of abnormal LFTs- Juan Berenguer, MD, PhD

International Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018

HCV in 2018- Jürgen Rockstroh, MD

International Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018

NAFLD: diagnostics, management and screening- Juan Macías, MD, PhD

International Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018